1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,930 | 8,240 | 17:32 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.04. | Devyser Diagnostics AB: Devyser announces that Chief Commercial Officer will leave the company | 124 | GlobeNewswire (Europe) | Devyser Diagnostics AB today announces that the company's Chief Commercial Officer (CCO), Theis Kipling, has decided to leave Devyser to take up a position with another company.
"During Theis' time... ► Artikel lesen | |
| 01.04. | Devyser Diagnostics AB: Devyser completes acquisition of CyberGene AB and carries out issue of compensation shares | 268 | GlobeNewswire (Europe) | Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, announces that the acquisition of all shares in CyberGene AB ("CyberGene") that was announced on 11 February 2026 has today been... ► Artikel lesen | |
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 04.03. | Devyser Diagnostics AB: Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing | 347 | GlobeNewswire (Europe) | Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing (NGS) assay for genetic analysis of thalassemia and sickle cell disease (SCD) available on the European... ► Artikel lesen | |
| 12.02. | Devyser Q4 2025 slides: Revenue growth and positive EBIT mark turnaround year | 1 | Investing.com | ||
| 12.02. | Devyser: Umsatzwachstum und positives EBIT markieren die Trendwende im Geschäftsjahr 2025 | 1 | Investing.com Deutsch | ||
| 12.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2025 | 214 | GlobeNewswire (Europe) | "The fourth quarter confirmed the positive earnings trend that we have seen throughout the year. Operating profit amounted to SEK 18.0 million (-3.7) for the quarter and to SEK 10.1 million (-62.3)... ► Artikel lesen | |
| 11.02. | Devyser Diagnostics AB: Devyser acquires Swedish company Cybergene AB and strengthens its position in the aneuploidy market | 816 | GlobeNewswire (Europe) | Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has entered into an agreement relating to the acquisition of 100 percent of the shares in Cybergene AB... ► Artikel lesen | |
| 28.01. | Devyser Diagnostics AB: Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products | 576 | GlobeNewswire (Europe) | Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA sequencing and array-based technologies, to provide Illumina sequencing instruments and related products... ► Artikel lesen | |
| 08.12.25 | Devyser Diagnostics AB: Devyser secures a four-year tender in France for Devyser Compact | 177 | GlobeNewswire (Europe) | Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in Marseille, France, valued up to SEK 9.5 million over a 48-month period.
This tender with Assistance... ► Artikel lesen | |
| 04.12.25 | Devyser Diagnostics AB: Health Canada grants IVD approval to Devyser's NGS-based chimerism test, the first of its kind in Canada | 185 | GlobeNewswire (Europe) | Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been granted approval as Class III In Vitro Diagnostic (IVD) medical devices by Health Canada. With this we... ► Artikel lesen | |
| 28.11.25 | Devyser Diagnostics AB: Devyser strengthens U.S. market presence with CMS pricing for PrenatalDetect RHD test | 829 | GlobeNewswire (Europe) | Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its final pricing determination for the company's PrenatalDetect RHD test (CPT 0536U) at $192. The non-invasive... ► Artikel lesen | |
| 25.11.25 | Devyser Diagnostics AB: Devyser advances U.S. clinical strategy with first patient enrolled in Devyser Accept cfDNA study | 364 | GlobeNewswire (Europe) | Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical trial, a key milestone in the company's efforts to bring a targeted next-generation sequencing solution... ► Artikel lesen | |
| 05.11.25 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period July to September 2025 | 197 | GlobeNewswire (Europe) | "I took over as the new CEO of Devyser on August 4th and it has been an exciting and eventful time. We are continuing to launch unique products and sign cooperation agreements with major companies in... ► Artikel lesen | |
| 04.11.25 | Devyser Diagnostics AB: Devyser CFTR achieves IVDR compliance, strengthening clinical confidence in cystic fibrosis diagnostics | 362 | GlobeNewswire (Europe) | Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its next-generation sequencing (NGS) based CFTR assay is now compliant under the European In Vitro Diagnostic Regulation... ► Artikel lesen | |
| 22.09.25 | Devyser Diagnostics AB: Bulletin from an Extraordinary General Meeting in Devyser Diagnostics AB (publ) held on 22 September 2025 | 187 | GlobeNewswire (Europe) | An Extraordinary General Meeting of Devyser Diagnostics AB (publ) ("Devyser" or the "Company") was held on Monday, 22 September 2025 at Bränningevägen 12, 120 54 Årsta. The main resolution passed at... ► Artikel lesen | |
| 22.07.25 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2025 | 261 | GlobeNewswire (Europe) | "A positive operating result was recorded in the second quarter. The effects of the cost-cutting program initiated at the beginning of the year can already be seen in both current costs and in the cost... ► Artikel lesen | |
| 30.06.25 | Devyser Diagnostics AB: Devyser launches Genomic Blood Typing assay: All blood groups, one simple test | 268 | GlobeNewswire (Europe) | Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation sequencing (NGS)-based solution that redefines molecular blood group research. Developed exclusively, this... ► Artikel lesen | |
| 29.04.25 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2025 | 507 | GlobeNewswire (Europe) | "A quarter has passed since I took over as acting CEO and it has been an eventful first few months. Despite the turbulent environment, marked by geopolitical uncertainty, we are able to report our second... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 71,34 | -1,16 % | Medtronic: During an Altaviva Implant, the Patient Talked About Lunch. That Was the Point | The Altaviva device was recently named a 2026 Edison Award winner in the Health, Medical and Biotech category. NORTHAMPTON, MA / ACCESS Newswire / April 21, 2026 / When Sarah Tapani sat in on one of... ► Artikel lesen | |
| HCA HEALTHCARE | 394,60 | -2,74 % | Cantor Fitzgerald reiterates HCA Healthcare stock rating at Overweight | ||
| LANTHEUS | 70,90 | -0,56 % | Here is Why Lantheus Holdings Inc (LNTH) Is Among the Best Medical AI Stocks to Invest In | ||
| ENVISTA | 23,600 | 0,00 % | Envista Holdings Corporation: Envista Reports Fourth Quarter 2025 Results | BREA, Calif., Feb. 5, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended December 31, 2025.
"With our... ► Artikel lesen | |
| CAREDX | 18,100 | 0,00 % | CareDx, Inc.: CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing | AlloSeq Nano delivers rapid, high-resolution HLA and ABO genotyping in a single assay through a streamlined, long-read workflow designed for transplant and donor typing laboratories.
CareDx, Inc.... ► Artikel lesen | |
| GT BIOPHARMA | 0,383 | +2,96 % | GT Biopharma, Inc.: GT Biopharma Reports Full Year 2025 Financial Results | Phase 1 trial evaluating GTB-3650 TriKE- continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5 Phase 1 basket trial evaluating... ► Artikel lesen | |
| SYNEOS HEALTH | - | - | BNK Invest, Inc.: Research Pages Built Around the Metrics Self-Directed Investors Actually Use | From dividend yield and payout history to ETF holdings and price-to-NAV, the focus is on helping investors get to the useful numbers faster. JERICHO, NY / ACCESS Newswire / April 20, 2026 / Most self-directed... ► Artikel lesen | |
| CARMAT | 0,049 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.03.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.03.2026.ISIN NameCA4013392051 GUARDIAN... ► Artikel lesen | |
| CHEMOMETEC | 46,500 | +0,87 % | Chemometec A/S: Adjustment of guidance for 2025/26 | ANNOUNCEMENT NO. 303 24 March 2026 Adjustment of guidance for 2025/26 Over the past period, ChemoMetec's most important market, the North American market for cell and gene therapy, has been affected... ► Artikel lesen | |
| POLAREAN IMAGING | 0,001 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 29.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 29.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 29.12.2025ISIN NameAU0000111395 PROSPECH... ► Artikel lesen | |
| ARRAIL GROUP | 0,203 | -100,00 % | XFRA I1D: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME Waehrung/Currency ISIN BIS/UNTIL
ARRAIL... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,650 | +0,56 % | Dax am Mittag leicht im Minus - FMC hinten | Frankfurt/Main - Der Dax hat sich am Mittwoch nach einem verhaltenen Start bis zum Mittag leicht in den roten Bereich gerutscht. Gegen 12:30 Uhr wurde der Leitindex mit rund 24.010 Punkten berechnet... ► Artikel lesen | |
| FRESENIUS | 43,390 | -0,89 % | EQS-PVR: Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
16.04.2026 /... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 38,130 | -0,42 % | RBC stuft Siemens Healthineers auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat Siemens Healthineers auf "Outperform" mit einem Kursziel von 55 Euro belassen. Dass Siemens das Szenario eines längeren Abspaltungsprozesses... ► Artikel lesen | |
| UNITEDHEALTH | 295,60 | +7,73 % | UnitedHealth Group Aktie steigt nach starken Quartalszahlen |
Das Unternehmen DEVYSER DIAGNOSTICS AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,010 (-0,12 %) liegt der Kurs bei 8,030 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.